0001363763-20-000002.txt : 20200324
0001363763-20-000002.hdr.sgml : 20200324
20200324164837
ACCESSION NUMBER: 0001363763-20-000002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200322
FILED AS OF DATE: 20200324
DATE AS OF CHANGE: 20200324
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Margolis Jeff Eliot
CENTRAL INDEX KEY: 0001573202
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16467
FILM NUMBER: 20738995
MAIL ADDRESS:
STREET 1: C/O AURORA CAPITAL LLC
STREET 2: 17 PARK AVENUE, #201
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RespireRx Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0000849636
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330303583
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 126 VALLEY ROAD
STREET 2: SUITE C
CITY: GLEN ROCK
STATE: NJ
ZIP: 07452
BUSINESS PHONE: (201) 444-4947
MAIL ADDRESS:
STREET 1: 126 VALLEY ROAD
STREET 2: SUITE C
CITY: GLEN ROCK
STATE: NJ
ZIP: 07452
FORMER COMPANY:
FORMER CONFORMED NAME: CORTEX PHARMACEUTICALS INC/DE/
DATE OF NAME CHANGE: 19920703
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2020-03-22
0
0000849636
RespireRx Pharmaceuticals Inc.
RSPI
0001573202
Margolis Jeff Eliot
RESPIRERX PHARMACEUTICALS INC.
126 VALLEY ROAD, SUITE C
GLEN ROCK
NJ
07452
1
1
1
0
SVP, CFO, Secretary & Teasurer
Common Stock
2020-03-22
4
J
0
4500000
A
4500000
D
Common Stock
2020-03-22
4
G
0
4250000
0
D
250000
D
Common Stock
2020-03-22
4
G
0
4250000
0
A
4280769
I
By Trust
Common Stock
2020-03-22
4
G
0
125000
0
D
125000
D
Common Stock
2020-03-22
4
G
0
125000
0
A
125208
I
By Trust
Common Stock
2020-03-22
4
G
0
125000
0
D
0
D
Common Stock
2020-03-22
4
G
0
125000
0
A
125207
I
By Trust
Common Stock
3076
I
By Trust
Common Stock
6153
I
By Trust
Common Stock
6153
I
By Trust
On March 21, 2020, Mr. Margolis agreed to forgive a portion of the accrued but unpaid compensation to which he was entitled pursuant to his employment agreement with RespireRx Pharmaceuticals Inc. (the "Company") equal to $153,000. On March 22, 2020, the Company issued to Mr. Margolis 4,500,000 shares of the Company's common stock, in exchange for the forgiveness of $153,000 of accrued and unpaid compensation, which equates to a per share value of $0.034 per share, the closing share price of the Company's common stock on Friday, March 20, the last business day prior to the transaction.
These dispositions and acquisitions reflect estate planning transactions. These securities are being contributed to trusts for the benefit of Mr. Margolis, his spouse and his children, as specified.
Mr. Margolis gifted these securities into a family trust for the benefit of Mr. Margolis's spouse. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
Mr. Margolis gifted these securities into a family trust for the benefit of his daughter. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
Mr. Margolis gifted these securities into a family trust for the benefit of his son. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
These securities are held in a trust for the benefit of Mr. Margolis. Mr. Margolis is a trustee of the trust.
These securities are held in trusts for the benefit of Mr. Margolis's daughter. Mr. Margolis is a trustee of these trusts. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
These securities are held in trusts for the benefit of Mr. Margolis's son. Mr. Margolis is a trustee of these trusts. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
/s/ Jeff Eliot Margolis
2020-03-24